

6044 Cornerstone Court West, Suite E San Diego, CA 92121

Tel: 1.858.829.3082 **Fax:** 1.858.481.8694

Email: info@bpsbioscience.com

Data Sheet

BCL-XL, His-tag

Human, recombinant, C-terminal His-tag

Catalog #: 50273

Lot #: 90116 **Conc.:** 2.94 mg/ml

Formulated in: 45 mM Tris-HCl, pH 8.0, 124 mM NaCl, 2.4 mM KCl, 10% glycerol, 225 mM imidazole and 3 mM DTT.

Stability: At least 6 months at -80°C. Avoid freeze/thaw cycles. Storing diluted protein is not recommended, if necessary use carrier protein (BSA 0.1 – 0.5%).

References:


- 1. Meng Y. *et al., Mol Cancer Ther.* 2008 Jul;**7(7):**2192-202.
- 2. Asakura T. *et al., Mol Int J Oncol.* 2008 Aug;**33(2):**389-95.

<u>Description</u>: Human BCL-XL, also known as B cell lymphoma XL and BCL-Xlong, a.a. 1-212, GenBank Accession No. NM_138578 with C-terminal His tag, MW = 24.6 kDa, expressed in an *E. coli* expression system.

Assay Description: Following the protocol for BPS Cat. #50223. Briefly, BCL-XL was combined with BCL-XL peptide ligand in TR-FRET assay buffer along with anti-His Tb donor and dyelabeled acceptor. Varying concentrations of ABT 199 were added and the reaction was incubated at room temperature for 2 hours followed by fluorescent intensity measurements.

<u>Application</u>: Useful for the study of apoptosis, screening inhibitors, and selectivity profiling.

Quality Assurance



OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.